negative regulation of cell-cell adhesion mediated by cadherin
Definition
Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of cell-cell adhesion mediated by cadherin. [GOC:obol]
Negative regulation of cell-cell adhesion mediated by cadherins is a crucial process that modulates cell-cell interactions and tissue organization. Cadherins are transmembrane proteins that mediate cell-cell adhesion through calcium-dependent interactions between their extracellular domains. They play a vital role in various developmental processes, tissue morphogenesis, and maintaining tissue integrity.
This regulatory process involves a complex interplay of molecular mechanisms that modulate cadherin function, including:
* **Cadherin phosphorylation:** Phosphorylation of cadherin cytoplasmic domains by kinases can weaken their association with the actin cytoskeleton, thereby reducing cell-cell adhesion.
* **Cadherin endocytosis:** Internalization of cadherin molecules from the cell surface via endocytosis reduces their availability for adhesion.
* **Cadherin proteolysis:** Cleavage of cadherin proteins by proteases, such as ADAM10 and ADAM17, can release soluble cadherin fragments, further reducing adhesion.
* **Cadherin binding proteins:** Various proteins can bind to cadherins and regulate their activity. For example, p120-catenin stabilizes cadherin adhesion, while beta-catenin promotes cadherin-mediated cell-cell junctions.
* **Cytoskeletal dynamics:** Regulation of the actin cytoskeleton, which provides mechanical support for cadherin-mediated junctions, can affect cell-cell adhesion.
* **Signal transduction pathways:** Signaling pathways, such as the Wnt and TGF-beta pathways, can influence cadherin function and cell-cell adhesion.
Negative regulation of cadherin-mediated cell-cell adhesion plays critical roles in various physiological processes, including:
* **Cell migration:** Reducing cell-cell adhesion allows cells to detach and migrate during development and wound healing.
* **Tissue remodeling:** Modulation of cell-cell adhesion is essential for tissue remodeling and morphogenesis.
* **Immune cell trafficking:** Regulation of cell-cell adhesion allows for the proper migration and infiltration of immune cells to sites of infection or injury.
* **Cancer metastasis:** Disruption of cell-cell adhesion through cadherin downregulation or dysfunction can contribute to cancer cell invasion and metastasis.
The intricate mechanisms involved in the negative regulation of cell-cell adhesion mediated by cadherins ensure proper cell-cell interactions, tissue organization, and cellular function. Understanding these processes is crucial for unraveling the complex dynamics of cell adhesion and its implications in development, disease, and tissue homeostasis.'
"
Proteins (3)
| Protein | Definition | Taxonomy |
|---|---|---|
| Neurogenic locus notch homolog protein 1 | A neurogenic locus notch homolog protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P46531] | Homo sapiens (human) |
| Vascular endothelial growth factor A | A vascular endothelial growth factor A, long form that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15692] | Homo sapiens (human) |
| Plasminogen | A plasminogen that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00747] | Homo sapiens (human) |
Compounds (47)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| aminocaproic acid | 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator. Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. | amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid | antifibrinolytic drug; hematologic agent; metabolite |
| 5-(n,n-hexamethylene)amiloride | 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring. 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity | aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines | antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker |
| bis(5-amidino-2-benzimidazolyl)methane | bis(5-amidino-2-benzimidazolyl)methane: aromatic diamidine which has a significant suppressive effect on the cytopathology & yield of respiratory synctial (RS) virus; RN given refers to parent cpd | ||
| gabexate | Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin. | benzoate ester | |
| nafamostat | nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic | benzoic acids; guanidines | |
| netropsin | Netropsin: A basic polypeptide isolated from Streptomyces netropsis. It is cytotoxic and its strong, specific binding to A-T areas of DNA is useful to genetics research. | ||
| pentamidine | pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease. Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | aromatic ether; carboxamidine; diether | anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic |
| tranexamic acid | Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage. | amino acid | |
| 4-phenylphenol | 4-phenylphenol: RN given refers to cpd without isomeric designation biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4. | hydroxybiphenyls | |
| calotropin | calotropin: structure in first source | cardenolide glycoside | |
| phenylguanidine | phenylguanidine: RN given refers to parent cpd | ||
| amiloride | amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid. Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) | aromatic amine; guanidines; organochlorine compound; pyrazines | diuretic; sodium channel blocker |
| 4-phenylbenzoic acid | 4-phenylbenzoic acid: RN given refers to 4-carboxylic cpd | ||
| leupeptin | aldehyde; tripeptide | bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor | |
| mci 9038 | peptide | ||
| dx 9065 | |||
| efegatran | efegatran: RN & structure given in first source; RN given refers to parent cpd (D)-isomer | ||
| 5-amidinoindole | |||
| 5-(4-piperidyl)isoxazol-3-ol | 5-(4-piperidyl)isoxazol-3-ol: structure given in first source; a partial agonist at the GABA-A receptor on cultured hippocampal neurones; antagonizes muscimol-stimulated benzodiazepine binding to rat cortical membranes | piperidines | |
| ono 3307 | ONO 3307: RN given refers to parent cpd; structure given in first source | ||
| 4-guanidinobenzoate | 4-guanidinobenzoate: RN given refers to parent cpd 4-guanidinobenzoic acid : Benzoic acid substituted at the para position by a guanidino group. | benzoic acids; guanidines | |
| melagatran | azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound | anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor | |
| pefabloc | |||
| beta-naphthamidine | beta-naphthamidine: RN given refers to parent cpd | ||
| razaxaban | razaxaban: structure in first source | ||
| dabigatran | dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. | aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines | anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor |
| benzamidine | carboxamidinium ion | ||
| 2-(4-chlorophenyl)guanidine | organochlorine compound | ||
| telaprevir | cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines | antiviral drug; hepatitis C protease inhibitor; peptidomimetic | |
| 3,7-dimethoxy-5,3',4'-trihydroxyflavone | 3,7-dimethoxy-5,3',4'-trihydroxyflavone: isolated from Veronia eremophila; structure given in first source 3',4',5-trihydroxy-3,7-dimethoxyflavone : A dimethoxyflavone that the 3,7-di-O-methyl derivative of quercetin. | dimethoxyflavone; trihydroxyflavone | EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite |
| amentoflavone | biflavonoid; hydroxyflavone; ring assembly | angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite | |
| hydroxygenkwanin | hydroxygenkwanin: isolated from leaves of Daphne genkwa | ether; flavonoids | |
| bms 740808 | 1-(3-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-6-(2'-(3-hydroxy-N-pyrrolidinyl)methyl-(1,1')-biphen-4-yl)-1,4,5,6-tetrahydropyrazolo-(3,4-c)-pyridin-7-one: structure in first source | ||
| proanthocyanidin a1 | procyanidin A1: from aqueous extract of peanut skin; structure in first source | flavonoid oligomer | |
| uk-356,202 | UK-356,202: structure in first source | ||
| n-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(l)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride | |||
| gw 813893 | |||
| lb 30057 | |||
| a-317567 | A-317567: acid sensing ion channel blocker; structure in first source | ||
| betrixaban | betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade. betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source | benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide | anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor |
| rpr 120844 | |||
| n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. | tripeptide; ureas | antiviral drug; hepatitis C protease inhibitor; peptidomimetic |
| m-chlorophenylguanidine | |||
| mk-7009 | vaniprevir : An azamacrocyclic compound that is a hepatitis C virus (HCV) NS3/4A protease inhibitor which is approved for the treatment of hepatitis C virus infections in Japan. vaniprevir: inhibits hepatitis C virus NS3/4a protease | azamacrocycle; carbamate ester; cyclopropanes; N-sulfonylcarboxamide; pyrrolidinecarboxamide | antiviral drug; hepatitis C protease inhibitor |
| grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
| phosphomannopentaose sulfate | phosphomannopentaose sulfate: structure in first source | ||
| rpx7009 | RPX7009: a beta-lactamase inhibitor; structure in first source |